Update on late stage, “intermediate atypical” mCRPC

According to a report this morning on the UroToday web site, Dr. Eric Small presented an update yesterday on so-called “intermediate atypical”, metastatic, castration-resistant prostate cancer (mCRPC) — at a general session of the 2015 meeting of the Society of Urologic Oncology in Washington, DC. … READ MORE …

Cisplatin as second-line chemotherapy for docetaxel-refractory prostate cancer

An Italian research team has published data from a small Phase II clinical trial suggesting that cisplatin + prednisone has activity in the treatment of men with castration-resistant prostate cancer (CRPC) who have already progressed after treatment with a docetaxel-based chemotherapy regimen. … READ MORE …